A variant typical of the Finnish population that protects against heart diseases was identified in the FinnGen genomic study coordinated by the University of Helsinki. The risk of developing heart diseases is roughly one-fifth lower in carriers of the variant compared to the population on average.

FinnGen data analysis environment, FinnGen Sandbox, is now one of the few certified secure operating environments in Finland. The certificate was granted on 20th April 2022 and is valid for five years.

We are happy to announce that the FinnGen data freeze 7 results and summary statistics are now publicly available!

We are pleased to announce that the FinnGen data freeze 6 results and summary statistics are now publicly available!

The public examination of the first FinnGen-based doctoral dissertation took place in October, 2021. Warm congratulations to Satu Strausz!

Boehringer Ingelheim has joined FinnGen, a large-scale academic – industry, genome research collaboration in Finland aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants.

The first sub-project of the FinnGen study to invite participants for further clinical examinations will begin in eastern Finland. The project will explore methods that are suitable for investigating the progression of Alzheimer's disease and other, less severe memory disorders. The aim is to improve early diagnostics of Alzheimer's disease and to increase understanding of its pathogenesis.